SCH-530348

(IUPAC) ime

Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate

Klinički podaci

Identifikatori

CAS broj

618385-01-6

ATC kod

B2C

PubChem^[1]^[2]

10077130

Hemijski podaci

Formula

C₂₉H₃₃FN₂O₄

Mol. masa

492.58 g/mol

InChI
InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1^Y Key: ZBGXUVOIWDMMJE-QHNZEKIYSA-N^Y

Farmakoinformacioni podaci

Trudnoća

Pravni status

SCH-530,348 je antagonist trombinskog receptora (PAR-1). On je baziran na prirodnom proizvodu himbacinu. Razvila ga je kompanija Šering-Plau (engl. Schering-Plough). SCH-530,348 je potentan lek za akutni koronarni sindrom, bol u prsima uzrokovan koronarnom bolešću arterija.^[3]

Ovaj lek je prešao u vlasništvo kompanije Merk (engl. Merck). On je poznat pod imenom Vorapaxar.

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Samuel Chackalamannil (2008). „Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity”. Journal of Medicinal Chemistry 51: 3061. DOI:10.1021/jm800180e.